Bristol-Myers to Pay up to $25M for Lexicon s Data, Clones | GenomeWeb

NEW YORK, Sept 27 – Lexicon Genetics (Nasdaq: LEXG) has signed the third-largest pharma Bristol-Myers Squibb (NYSE: BMY) to a database access and license agreement worth as much as $25 million dollars, the companies said Wednesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.